OnKure Therapeutics (NASDAQ:OKUR) Receives “Buy” Rating from HC Wainwright

OnKure Therapeutics (NASDAQ:OKUR)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 127.53% from the stock’s previous close.

Other analysts have also issued reports about the stock. Oppenheimer began coverage on shares of OnKure Therapeutics in a research note on Thursday, October 10th. They set an “outperform” rating and a $35.00 target price on the stock. Lifesci Capital upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, October 10th.

OnKure Therapeutics Price Performance

Shares of OKUR stock opened at $17.58 on Friday. The company has a market capitalization of $58.72 million, a price-to-earnings ratio of -1.05 and a beta of 0.21. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $77.60.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.13). As a group, equities analysts forecast that OnKure Therapeutics will post -3.87 EPS for the current fiscal year.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.